BioAtla, Inc.

BioAtla, Inc. is a biotechnology company focused on the development of conditionally active biologics (CABs) for cancer treatment. Founded with a mission to enhance cancer therapies, BioAtla emphasizes the modulation of antibodies and other proteins to improve target specificity and minimize side effects in oncological applications. The company's proprietary CAB technology is designed to activate therapeutics specifically in the tumor microenvironment, thus sparing healthy tissues. This precision approach holds potential for enhancing the efficacy and safety profile of cancer drugs. BioAtla's diverse pipeline includes a range of therapies applied to various solid and hematologic tumors, reflecting its integral role in advancing targeted cancer treatments. In the broader biotechnology market, BioAtla signifies a shift towards personalized and precision medicine, aligning with contemporary trends that prioritize targeted therapeutic interventions. Headquartered in San Diego, California, BioAtla collaborates with partners across the pharmaceutical and healthcare sectors to push the boundaries of treatment possibilities for cancer patients worldwide.